Gilead Falls as Drug Has Only Small Benefit in Large Trial

Published June 1, 2020

Gilead Sciences Inc.’s drug remdesivir showed only a limited benefit in a large trial of more moderate patients with Covid-19, a result that may shift perceptions of the therapy already cleared for use in severe cases of the disease.